Researchers at the RIKEN Center for Developmental Biology will treat the first patient in its clinical trial testing an induced pluripotent stem cell-based treatment for age-related macular degeneration.

An open mind and collaborative spirit have taken Hans Clevers on a journey from medicine to developmental biology, gastroenterology, cancer, and stem cells.

A key mutation turns healing cells into cancer promoters.

Researchers created a new high-throughput tool to hunt for therapies that remyelinate the nervous system.

Editor's Note: This second part of a two-part series looks at the Internet's growing capabilities for scientists. For more and more researchers, the network is making crucial information resources available online. In addition, several ongoing demonstration projects in remote instrument control and in networked laboratories suggest a much-changed future for science as a result of the Internet. The first part of this series, which ex

Editor's Note: This second part of a two-part series looks at the Internet's growing capabilities for scientists. For more and more researchers, the network is making crucial information resources available online. In addition, several ongoing demonstration projects in remote instrument control and in networked laboratories suggest a much-changed future for science as a result of the Internet. The first part of this series, which ex

Understanding biology’s software—the rules that enable great plasticity in how cell collectives generate reliable anatomies—is key to advancing tissue engineering and regenerative medicine.

Chairman: Arnold Levine, chairman, department of molecular biology, Princeton University Barry Bloom, Weinstock Professor and Howard Hughes Medical Institute (HHMI) investigator, department of microbiology and immunology, Albert Einstein College of Medicine, New York Rebecca Buckley, professor of pediatrics and immunology, Duke University Medical Center Charles Carpenter, chairman, Office of AIDS Research Advisory Committee; professor of medicine,Brown University School of Medicine Don

But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy

But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy